Objective: To investigate the relationship among affective status, cognitive function, and gait in depressed patients and to evaluate the effects of treatment of depression on gait and cognitive function.
M
ultiple connections link movement to affect and cognitive function in a complex way. Changes in affect may predispose to and exacerbate changes in motor control and cognitive function, whereas changes in cognitive function may also be related to affect and motor control. Moreover, changes in the latter may predispose to changes in affect and cognitive function. Evidence for the existence of this ''triangle'' comes from several sources. For example, late-life depression with subjective memory complaints may be associated with an increased risk of developing dementia, 1 and gait alterations may predict the development of dementia, as much as 6 years into the future. 2, 3 On the other hand, motor changes seen in depressed patients and those with pseudodementia may include bradykinesia, hypomimia, speech disturbances, and balance disturbances. 4 A study of late-onset depressive disorder that compared individuals with and without depression showed significant differences in the presence and type of neurological signs between patients with depression and control subjects. Several differences ceased to be significant after adjusting for major depression and the use of major tranquilizers, but motor signs remained significantly different, suggesting that late-life depression is associated with organic changes such as those that are common in patients with a stroke or neurodegenerative disease. 5 Depression has been associated with alterations in locomotion and increased fall risk among older adults. 6, 7 Indeed, the most common risk factors for falls in the elderly include gait changes, cognitive function, and depression. 7 The links between depression and falls, however, are not fully clear, 8 partly because of the confounding effects of medications. Epidemiological studies indicated that older adults who are more depressed have an increased risk of falls and fractures compared with their aged-matched peers, and this association apparently persists even after adjustment for potential confounding effects, such as medication usage.
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Patients with major depression have been shown to walk more slowly, with decreased push-off and more time spent with both feet on the ground. 12, 13 These gait changes, however, do not necessarily explain the increased risk of falls associated with depression. 14Y16 One possibility is that these 2 syndromes simply share common risk factors 17 or common pathophysiological mechanisms. For example, depression may not only lead to a slowed gait, but it could induce gait unsteadiness and a reduction in the ability to maintain a stable walking pattern. Indeed, cross-sectional studies suggested that individuals who report more signs of depression tend to be less steady. 18, 19 In addition, because depression may lead to reduced cognitive performance, in particular, executive function 20 and because gait is related to this cognitive domain, 3, 8, 21 it is possible that these changes in cognitive function actually precipitate the changes in gait and fall risk in older adults. The purpose of the present investigation was to further examine this triad of affect, motor function, and cognitive function to better understand how gait and cognitive function are related to depression. This prospective, open-label study evaluated the relationship among affect, cognitive function, and gait of depressed patients and quantified the effects of pharmacological treatment of depression on gait and cognitive function. 
MATERIALS AND METHODS

Subjects
Clinical Evaluation and Assessments
All study patients were initially interviewed by a psychiatrist (A.S.) who confirmed the diagnosis of clinical depression. The medication selected for therapy was based on clinical judgment using current standard guidelines. The Hamilton Depression Rating Scale (HAM-D) 23 was used to assess the affective status, the Mini-Mental State Examination (MMSE) 24 was used to provide a gross general measure of cognitive function, and Barthel's Index of Instrumental Activities of Daily Living (IADL) 25 was used to measure functional independence. All assessments were performed at baseline and after approximately 10 weeks of treatment with antidepressants, using a drug from the selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) groups that were titrated to therapeutic doses to reach maximal clinical improvement.
Walking Protocol
The subjects were instructed to walk on level ground for 2 minutes at their normal pace along a 25-m-long, 2-m-wide hallway under usual lighting conditions and to turn around and continue walking when they reached the end of the hallway. They were all tested under the same conditions at baseline and after the course of therapy. The patients were protected by the study coordinator (A.S.) who walked a few steps behind them, taking care not to interfere or set the pace.
Assessment of Gait
Previously described methods were used to quantify gait during the 2-minute walk. 18, 26, 27 Briefly, force-sensitive insoles were placed in the subject's shoe to measure the gait rhythm and the timing of the gait cycle (ie, the stride time). These inserts produce a measure of the force applied to the ground during ambulation. A small lightweight (5.5 Â 2 Â 9 cm; 0.1 kg) recorder was worn on the ankle and held in place by an ankle wallet. The stride time or duration of the gait cycle (time from initial contact of one foot to subsequent contact of the same foot) was determined for each stride during the 2-minute walk from the force signal by applying a previously validated algorithm that locates initial contact times (and hence the stride time) by finding large increases and changes in the slope of the force. 27 Swing time percentage was also determined.
To focus on the assessment of the dynamics of continuous ''normal'' walking and each subject's own ''natural'' dynamics and to ensure that the analysis was not influenced by atypical strides (eg, the turning at the end of the hallway), a median filter was applied to each subject's time series to remove data points that were 3 SDs greater than or less than the median value. 18, 27 Stride time variability (ie, the magnitude of the strideto-stride fluctuations in the gait cycle duration) was calculated by determining the SD of each subject's stride time. 16, 18, 27 Stride-tostride variability reflects gait unsteadiness and arrhythmicity and has been shown to prospectively predict falls. 16, 18, 27, 28 Because the left and right feet generally behaved similarly, we report only the values for the right foot. Average gait speed was determined by measuring the average time the subject walked the middle 8 m of the 25-m walk during the 2 minutes of testing. Average stride length was by determined by multiplying gait speed by the average stride time. Gait asymmetry was defined as 100 times the absolute value of the natural logarithm of the ratio between the left foot and right foot swing times, as previously described. 29 Cognitive Assessment To permit summarizing the performance in each cognitive domain across different types of outcome parameters (eg, accuracy, RT), each outcome parameter was normalized and fit to an IQ-like scale (mean, 100; SD, 15) in an age-and educationspecific fashion. As described previously, 30 normalized subsets of outcome parameters were averaged to produce 5 summary scores, each indexing a different cognitive domain: memory, executive function, attention, information processing speed, visual spatial function, and hand-eye coordination. The information processing index is based on performance on low-and medium-load stages of the Staged Information Processing Speed test. The executive function index score reflects accuracy and overall performance on tasks that maximally tax executive function (eg, Stroop Interference). In contrast, the attention index score mainly reflects RTs for tasks that require the patient to focus (eg, Stroop No Interference [Meaning]) but do not stress executive function per se. These index scores and a Global Cognitive Score, computed as the average of these index scores, provided a measure of cognitive function. Recent articles have described the validity of the battery compared with traditional measures, the reliability of its summary index scores, its test-retest reliability, and its sensitivity to disease state and therapeutic intervention.
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Statistical Analysis
The Wilcoxon signed ranks tests were used to compare performance before and after treatment by antidepressants. Spearman correlation coefficients were used to quantify associations among variables. All P values reported are based on 2-sided comparisons. A P value of e0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 10 (SPSS, Chicago, Ill).
RESULTS
Baseline Characteristics
The study cohort consisted of 19 patients (15 women and 4 men; mean age, 68.6 T 9.1 years). They were all diagnosed as being depressed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria, and all experienced dysthymia. They were all functioning independently in the community. Before the initiation of therapy, the HAM-D scores were relatively high (Table 1) , consistent with the diagnosis of clinical depression. Mild alterations in cognitive function and gait were also observed (Tables 2 and 3 ) (eg, as seen in the ability to perform independent activities of daily living and in the performance on the MMSE).
Relationship Among Depression, Gait, and Cognitive Function at Baseline
Baseline depressive symptoms, as measured by the HAM-D scores and gait asymmetry, were not related (r = 0.48; P = 0.097); in fact, HAM-D scores were not significantly associated with any gait measure or any of the neuropsychological indexes of cognitive function at baseline.
Effects of Therapy
All 19 patients completed the study. The mean treatment duration was 10.4 T 4.7 weeks. Two subjects were treated with SNRIs (venlafaxine), and the other 17 patients were treated with SSRIs (eg, fluvoxamine, sertraline, paroxetine). One 77-yearold woman whose baseline and postYHAM-D scores were 20 and 19, respectively, did not respond well to the antidepressant treatment (see Table 1 , subject 16). She received 100 mg/d sertraline, a prescription that was identical to that of 4 other patients. Subjects generally showed a marked reduction in depressive symptoms (mean percentage change in HAM-D for all subjects, 55.7% T 14.7%; range, 5.0%Y72.7%) ( Table 1 and 2) .
Tables 1Y3 summarize the effects of the antidepressant therapy. As anticipated, the therapy significantly (P G 0.001) improved the affective state (Table 1) . Instrumental Activities of Daily Living and MMSE scores also improved (P G 0.002). All of the neuropsychological indexes of cognitive function, with the exception of motor skills, also significantly improved after antidepressant therapy (Table 3 ). In addition, there were small improvements in multiple aspects of gait including gait speed (P G 0.033), stride time variability (P G 0.036), and asymmetry (P G 0.038) ( Table 2 ). Figure 1 portrays an example of how left right gait asymmetry improved in response to therapy. We investigated the association between changes in depressive symptom changes in the other measures that showed a significant response to therapy. Change in HAM-D scores were weakly associated with changes in MMSE scores (r = j0.47; P = 0.044). Changes in the HAM-D scores tended to be associated with changes in the executive function index (r = 0.41; P = 0.084), but were not significantly associated with changes in any of the other neuropsychological indexes of cognitive function (P 9 0.17) or changes IADL (P = 0.43). Changes in HAM-D scores were not significantly correlated with changes in gait measures (P 9 0.35). The lack of an association between the changes in HAM-D scores and gait and cognitive function generally persisted if the one subject who did not respond to therapy had been excluded from the analysis, except that the association with the change in executive function would then became significant (P = 0.028). On the other hand, changes in neuropsychological performance, for example, as measured by the Global Cognitive Score, were associated with changes in IADL scores (r = j0.49; P = 0.034), 
DISCUSSION
Previous studies have shown that major depression is associated with changes in gait 12Y14 and cognitive function. 2, 20 Here we extend those findings and show that cognitive function and gait are altered even among patients with dysthymia (but without major depression). Further, we demonstrate that in addition to its effect on depressive symptoms, antidepressant pharmacological therapy brings about improvements in gait (speed, stride variability, and swing asymmetry) and cognitive function. These changes in gait and cognitive function were not strongly correlated with the changes in the in the affective state. Interestingly, however, improvement in cognitive function was associated with improvement in certain aspects of gait. The lack of a strong correlation between changes in depressive symptoms, on the one hand, and modifications in gait and cognitive function, on the other, suggests that the relationship among affect, locomotion, and cognitive function is weak, nonlinear, and/or multifactorial. The lack of correlation might also result from the fact that the study population had only moderate degrees of depression and did not include patients with major depression in whom a more robust correlation might have been observed. Another possibility is that there is a third mediator or covariate that was not measured in the present study.
Pharmacological therapy dramatically enhanced the affective status of our patients and had a smaller impact on gait parameters (speed, steadiness, and asymmetry). A crosssectional study focusing on predisposing factors for falls in older adults in different geriatric care settings concluded that among the antidepressants, SSRIs, but not SNRIs, were associated with falls. 33 Studies of the effects of SSRIs in depressed patients with Parkinson disease have shown somewhat mixed findings, with some suggesting that SSRIs may interfere with motor behavior. 34, 35 In the present study, all but 2 patients received SSRIs. Thus, our results are somewhat surprising in that they suggest that therapy with SSRIs is not responsible for the deterioration in locomotion in depressed patients, but rather that it is associated with improved motor function. It should be borne in mind that our population was younger (mean age, 68.6 years) than the population in the above-mentioned study (mean age, 83.3 years), a factor that might explain the differences in the findings of other studies.
A recently published study 36 showed that methylphenidate treatment improved gait and cognition in patients with Parkinson disease, implying that improved dopamine reuptake has a beneficial effect upon both gait and cognitive function. The link among depression, cognition, and motor pathways is highly complex, with the dopaminergic and serotoninergic pathways representing only 1 facet of this interlocking system. It would be interesting to determine whether, consistent with data from animal studies, the clinical antidepressant action of SSRIs is reversed by acute administration of a receptor antagonist selective for D2/D3-like receptors (eg, 200 mg/d sulpiride) in the mesolimbic dopamine system. Sulpiride, a neuroleptic with a debatable antidepressant activity, is also known to cause extrapyramidal side effects and falls. Although it slightly improved subjective well-being in a control group, sulpiride caused a substantial reinstatement of depressed mood in antidepressant-treated patients. 37 These data are consistent with the hypothesis that sensitization of D2-like receptors may be central to the clinical action of SSRIs. 37 One might argue that the observed effects of antidepressant therapy on cognitive function and, on a lesser degree, gait were a result of decreased motor slowing and not a result of improved cognitive function. There is, however, some evidence that effect of ''motor slowing'' on the cognitive measures was relatively small or nonexistent. The hand-eye coordination test has a relatively major motor component, and yet, it did not improve significantly in response to the medications (P = 0.39). Similarly, tapping performance, a test with large motor performance and minimal cognitive input, did not improve (P 9 0.25). In contrast, those tests that tax cognitive function significantly improved in response to the medication (eg, executive function, P = 0.009; memory, P = 0.001; attention, P = 0.003). The contrast suggests that motor slowing was not the primary reason for the observed changes.
In summary, the present study demonstrated that depression is associated with gait and cognitive impairment and that these domains improve with antidepressant medication. This study was limited by a relatively small sample size, an open-label design, and the fact that all patients experienced dysthymia and not major depression, factors that might explain the weak correlations that were observed. Further study should also examine longer-term effects. Although additional study is needed to more fully determine whether the changes in gait shown in the present study were induced by a drug effect or by the changes in cognitive function and/or mood, the present results underscore the complex relationships between these different factors and indicate that certain aspects of gait may actually improve in response to antidepressant therapy.
